Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.
MD Anderson and Rigel Pharmaceuticals announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia and other hematologic cancers.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson Cancer Center, has been honored with the E. Donnall Thomas Lecture and Prize from the American Society of Hematology (ASH, for her groundbreaking research to develop and advance innovative cell therapies for cancer using natural killer (NK) cells.
Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.
A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective in patients with locally advanced pancreatic cancer, yielding a higher progression-free survival (PFS) and overall response rate (ORR).
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
The James P. Allison Institute at MD Anderson hosted its inaugural scientific symposium on Nov. 10, bringing together more than 400 leading scientists in immunotherapy and immunobiology.
Howard Meyers, of Dallas, Texas, a member of The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), has committed $25 million to The University of Texas MD Anderson Cancer Center to establish the Meyers Institute for Oncology Nursing.
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates the most advanced computational and data science approaches with the institution’s extensive scientific and clinical expertise to significantly improve patient’s lives by transforming cancer care and research.
MD Anderson and Jazz Pharmaceuticals announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational, and clinical cancer research from MD Anderson experts. irectly into the liver for patients with metastatic uveal melanoma.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include positive results from a Phase I trial for patients with TP53-mutant acute myeloid leukemia, a novel machine learning platform to identify cancer biomarkers from liquid biopsies, a tumor-specific multi-microRNA delivery system to improve treatment outcomes in glioblastoma, a combination strategy to overcome treatment resistance in KRAS-mutated pancreatic cancer, and a new target for improving treatment response in patients with stomach cancer that has metastasized to the peritoneal cavity.
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.
Perioperative immunotherapy plus neoadjuvant chemotherapy significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC) compared to chemotherapy alone. Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society of Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center.
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy. The study was published today in Nature Communications.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy, suggesting that lactic acid-producing bacteria present in various cancers may serve as novel therapeutic targets. The study, published today in Cancer Cell, reported that a particular bacterial species, Lactobacillus iners (L. iners), caused cancer cells to respond to radiation by rewiring metabolic signaling pathways to resist treatment. The researchers also found that L. iners was associated with poorer clinical outcomes in patients with cervical cancer.
The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring presentations and discussions on genomics, immunity and inflammation, computational approaches for spatial biology, and emerging technologies that are driving the next wave of cancer breakthroughs.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
